BioCentury
ARTICLE | Company News

Cue Biopharma in autoimmune deal with Merck

November 17, 2017 7:56 PM UTC

On Nov. 16, Merck & Co. Inc. (NYSE:MRK) partnered with Cue Biopharma Inc. (Cambridge, Mass.) to develop biologics to treat autoimmune diseases. Cue will receive an undisclosed upfront payment, and is eligible for $374 million in milestones, plus tiered royalties.

The companies will use the biotech's Cue Biologics platform to develop biologics engineered to selectively modulate disease-relevant T cell subsets against "multiple disease targets," Cue said. The company declined to comment on the deal...